MSCs can inhibit inflammatory factors, such as MCP-1 and HMGB-1, and inhibit activation of the NF-κB, JAK/STAT, and Akt/GSK3β signaling pathways to alleviate the lesions in SLE. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.